Abstract
Parametric mapping fosters the role of cardiovascular magnetic resonance in its unique capability to evaluate myocardial tissue without the use of contrast agents. While there is a large body of literature highlighting the role of T1 mapping, the role of T2 mapping is less clear. This review aims to address the latest evidences for added clinical value of T2 mapping. T2 mapping shows superior diagnostic accuracy in myocarditis, transplant rejection, and cardiac involvement in lupus erythematosus. Moreover, T2 values predict major adverse cardiovascular events in myocarditis and enable therapy monitoring in lupus erythematosus as well as after heart transplantation. In ischemic cardiomyopathy, T2 mapping discriminates acute from chronic injury and provides additional information for patient risk stratification. T2 mapping provides a robust, quantifiable non-contrast-enhanced myocardial biomarker. However, there is no standardization in acquisition protocols, which formulates the future need for standardization ahead of multi-center trails.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
